Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Reda G Yousef"'
Autor:
Ibrahim H. Eissa, Reda G. Yousef, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed Ismail, Hazem Elkady, Ahmed M. Metwaly
Publikováno v:
ACS Omega, Vol 9, Iss 14, Pp 15861-15881 (2024)
Externí odkaz:
https://doaj.org/article/b004c67ecc314a46bfafaba99f91a655
Autor:
Ibrahim H. Eissa, Muhammad Abd ElGayed Bkrah, Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Dalal Z. Husein
Publikováno v:
Journal of Chemistry, Vol 2024 (2024)
A new nicotinamide derivative, (E)-N-(4-(1-(2-(4-benzamidobenzoyl)hydrazone)ethyl)phenyl)nicotinamide, was designed as a VEGFR-2 inhibitor. Utilizing the density functional theory (DFT) calculations, the three-dimensional structure of the designed co
Externí odkaz:
https://doaj.org/article/6562b0ebed124687ba78da8bd3270b1e
Autor:
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Hesham A El-Mahdy, Hazem Elkady, Ahmed M Metwaly
Publikováno v:
Evolutionary Bioinformatics, Vol 19 (2023)
The overexpression of the Epidermal Growth Factor Receptor (EGFR) marks it as a pivotal target in cancer treatment, with the aim of reducing its proliferation and inducing apoptosis. This study aimed at the CADD of a new apoptotic EGFR inhibitor. The
Externí odkaz:
https://doaj.org/article/646090e38afb4cf69efe8364aced2105
Autor:
Ibrahim H. Eissa, Reda G. Yousef, Mostafa A. Asmaey, Hazem Elkady, Dalal Z. Husein, Aisha A. Alsfouk, Ibrahim M. Ibrahim, Mohamed A. Elkady, Eslam B. Elkaeed, Ahmed M. Metwaly
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 12, Pp 101852- (2023)
VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhib
Externí odkaz:
https://doaj.org/article/fb21ad7bdf7e4aa894fa67c446b73100
Autor:
Prof. Ibrahim H. Eissa, Reda G. Yousef, Dr. Hazem Elkady, Dr. Eslam B. Elkaeed, Dr. Aisha A. Alsfouk, Dr. Dalal Z. Husein, Ibrahim M. Ibrahim, Prof. Mohamed M. Radwan, Prof. Ahmed M. Metwaly
Publikováno v:
ChemistryOpen, Vol 12, Iss 10, Pp n/a-n/a (2023)
Abstract A computer‐assisted drug design (CADD) approach was utilized to design a new acetamido‐N‐(para‐fluorophenyl)benzamide) derivative of the naturally occurring alkaloid, theobromine, (T‐1‐APFPB), following the pharmacophoric feature
Externí odkaz:
https://doaj.org/article/e1acf877554341aa89fd38829d8acfae
Autor:
Reda G. Yousef, Alaa Elwan, Ibraheem M. M. Gobaara, Ahmed B. M. Mehany, Wagdy M. Eldehna, Souad A. El-Metwally, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 2206-2222 (2022)
New nicotinamide derivatives 6, 7, 10, and 11 were designed and synthesised based on the essential features of the VEGFR-2 inhibitors. Compound 10 revealed the highest anti-proliferative activities with IC50 values of 15.4 and 9.8 µM against HCT-116
Externí odkaz:
https://doaj.org/article/c09df274b94249cb8a1c29016714c3fc
Autor:
Reda G. Yousef, Albaraa Ibrahim, Mohamed M. Khalifa, Wagdy M. Eldehna, Ibraheem M. M. Gobaara, Ahmed B. M. Mehany, Eslam B. Elkaeed, Aisha A. Alsfouk, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 1389-1403 (2022)
A library of modified VEGFR-2 inhibitors was designed as VEGFR-2 inhibitors. Virtual screening was conducted for the hypothetical library using in silico docking, ADMET, and toxicity studies. Four compounds exhibited high in silico affinity against V
Externí odkaz:
https://doaj.org/article/8d0e025758924bbe9f7388baf0e479e8
Autor:
Ibrahim H. Eissa, Reda G. Yousef, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mohamed S. Alesawy, Hazem Elkady, Ahmed M. Metwaly
Publikováno v:
PLoS ONE, Vol 18, Iss 3 (2023)
A new semisynthetic derivative of the natural alkaloid, theobromine, has been designed as a lead antiangiogenic compound targeting the EGFR protein. The designed compound is an (m-tolyl)acetamide theobromine derivative, (T-1-MTA). Molecular Docking s
Externí odkaz:
https://doaj.org/article/c116d5f391d849f7ab194788d0e3ace0
Autor:
Ibrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Bshra A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Eslam B. Elkaeed, Ahmed M. Metwaly
Publikováno v:
Life, Vol 13, Iss 1, p 191 (2023)
A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid
Externí odkaz:
https://doaj.org/article/d0b8043f6d5844d2b16d0de77a697bbf
Autor:
Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Ibraheem M. M. Gobaara, Hanan A. Al-ghulikah, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa
Publikováno v:
Molecules, Vol 27, Iss 22, p 7719 (2022)
(E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide (compound 10) was designed as an antiangiogenic VEGFR-2 inhibitor with the essential pharmacophoric structural properties to interact with the catalytic pocket of
Externí odkaz:
https://doaj.org/article/8ffc0b98a2314df081995f65fd606add